STADA Arzneimittel AG: STADA takeover offer by Bain Capital and Cinven successful
Bad Vilbel, August 18, 2017 - Nidda Healthcare Holding AG, the acquiring company of Bain Capital und Cinven, announced today that 63.85 percent of the outstanding STADA shares were tendered within the scope of the renewed voluntary public takeover offer. The minimum acceptance threshold of 63 percent was thus exceeded. The acceptance period ended on August 16, 2017 at midnight (24:00 CEST).
As stipulated in the German Securities Acquisition and Transfer Act (WpÜG), after the achievement of the minimum acceptance rate, a further acceptance period of two weeks follows. This commences on August 19, 2017 and expires on September 1, 2017. During this period, STADA shareholders who have not yet accepted the offer have the opportunity to tender their shares.
Contact: STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org
Or visit us in the Internet at www.stada.com.
18.08.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel
Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: email@example.com Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service